NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)	B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, Tumor Virus Infections, cytokine release syndrome, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease	Recruiting	Phase 2 / Phase 3	2026-03-30		NCT07502118

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Health Institutes of Turkey	19

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ankara Bilkent City Hospital - Hematology Clinic	Ankara	Turkey (Türkiye)	1
Ankara Etlik City Hospital - Hematology Clinic	Ankara	Turkey (Türkiye)	1
Hacettepe University Faculty of Medicine - Department of Internal Medicine, Division of Hematology	Ankara	Turkey (Türkiye)	1
University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital	Ankara	Turkey (Türkiye)	1